Arthramid is a patented 2.5% injectable polyacrylamide hydrogel (iPAAG) used in the management of osteoarthritis in animals.
Following injection, Arthramid integrates into the synovial membrane to help support joint function and long-term synovial health.
Backed by more than 25 years of Contura research, Arthramid has been registered for veterinary use in New Zealand since 2020.
